HC Wainwright lowered shares of BioAtla (NASDAQ:BCAB - Free Report) from a buy rating to a neutral rating in a research note published on Wednesday morning, MarketBeat reports.
Separately, JMP Securities restated a "market outperform" rating and set a $5.00 price objective on shares of BioAtla in a report on Monday, September 16th.
Read Our Latest Research Report on BioAtla
BioAtla Stock Performance
Shares of NASDAQ BCAB traded down $0.18 during midday trading on Wednesday, hitting $2.01. 888,339 shares of the company's stock were exchanged, compared to its average volume of 841,020. BioAtla has a 12 month low of $1.14 and a 12 month high of $4.02. The company's 50 day moving average price is $1.92 and its 200 day moving average price is $1.88.
BioAtla (NASDAQ:BCAB - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.12. The company had revenue of $11.00 million during the quarter. During the same quarter in the prior year, the company posted ($0.70) EPS. As a group, equities research analysts predict that BioAtla will post -1.52 EPS for the current year.
Institutional Trading of BioAtla
Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in BioAtla by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 2,099,037 shares of the company's stock worth $7,221,000 after acquiring an additional 17,667 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of BioAtla in the second quarter valued at approximately $872,000. Scion Asset Management LLC purchased a new stake in shares of BioAtla during the 2nd quarter valued at approximately $869,000. Massachusetts Financial Services Co. MA boosted its holdings in BioAtla by 5.2% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 569,332 shares of the company's stock worth $1,002,000 after buying an additional 28,133 shares during the period. Finally, Bank of Montreal Can grew its stake in BioAtla by 55.1% in the 2nd quarter. Bank of Montreal Can now owns 404,198 shares of the company's stock valued at $554,000 after buying an additional 143,521 shares in the last quarter. 77.23% of the stock is currently owned by institutional investors.
About BioAtla
(
Get Free Report)
BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.
Read More
Before you consider BioAtla, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioAtla wasn't on the list.
While BioAtla currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
